Invitalia: CEO Bernardo Mattarella visits BSP Pharmaceuticals in Latina

“Today we are visiting a company born from a technological and entrepreneurial intuition, which has taken over a disused site and has become a world excellence, also enhancing Italian research and with great attention to human resources. Through the Development Contract, which Invitalia manages on behalf of the Ministry of Enterprises and Made in Italy, we have supported BSP’s investments of about € 400 million through 4 different programmes, which have also increased the workforce by over 1,000 people. This is the quintessence of our work: supporting entrepreneurs who have enlightened ideas and a sense of development”.

With these words, Bernardo Mattarella, CEO of Invitalia, the National Development Agency, commented on the visit to BSP Pharmaceuticals, the Latina-based company, a global leader in the provision of services to the pharmaceutical industry and focused on innovative oncology and the production of new biopharmaceuticals for immunotherapy.

Founded in 2006 by Cav. Aldo Braca, with a project for the conversion of the disused former Tetrapak industrial site, the company now operates as a Contract Manufacturing & Development Organisation (CDMO), exporting almost all of its services to over 80 countries and serving the world’s leading pharmaceutical companies.

BSP Pharmaceuticals has been awarded in the last 7 editions of the World ADC Summit in San Diego, California, as the world’s best supplier of ADC (Antibody Drug Conjugates).

Since 2015, the company has signed 4 Development Contracts with Invitalia, aimed at:

• the increase in the production capacity of the Latina site (located on a campus of about 30 hectares), through the redevelopment of the existing sterile departments and the construction of new operating units
   
• supporting industrial research and experimental development projects, for the development of innovative biopharmaceuticals for oncological therapeutic treatments and monoclonal antibodies with antiviral, cytotoxic and immunotherapeutic action.

The 4 projects have brought about € 400 million of investments to the area, for which Invitalia has approved € 67.2 million in financial benefits (5.3 of which co-financed by the Lazio Region) and over 1,000 new jobs.

“BSP Pharmaceuticals is now recognised by the world of oncology research as one of the world’s leading centres of excellence, but the collaboration with Invitalia remains strategic for us,” said Aldo Braca, Chairman and CEO of BSP, “because it is also thanks to the support of these public incentives that we have never stopped investing in experimentation and research into new technological solutions to be made available in the fight against tumours”.

In Italy, since 2012 Invitalia has approved a total of 438 Development contracts, with investments of € 18.1 billion, supported by over € 6 billion in financial benefits and an employment impact of over 250 thousand employees.

In the Lazio Region, in the same period, 19 projects were approved by Invitalia, with investments of € 935 million, financial benefits granted for about € 288 million, with an employment impact of 10,000 jobs.

 
The Development Contract, promoted by the Ministry of Enterprises and Made in Italy and managed by Invitalia, is a tool that promotes the implementation of strategic and innovative development programmes, of significant size, in order to strengthen the country’s production structure.